Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06830031 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Study acronym: C402
StatusRecruiting
PhasePhase 1
Started2025-03-25
View on ClinicalTrials.gov ↗
This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.

Amendment history 2 changes detected by DataLookout

2026-09-12
Primary completion pushed: 2026-03-09 → 2029-04-28
2026-09-12
Completion pushed: 2026-05-11 → 2029-09-18
Trial Details
NCT Number NCT06830031
Lead Sponsor Shanghai Exuma Biotechnology Ltd.
Collaborators: Institute of Hematology & Blood Diseases Hospital, China
Conditions Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes, Follicular Lymphoma Grade 3B, PMBL, HGBL With MYC and BCL2 and/or BCL6 Rearrangements, HGBL, Nos
Enrollment 18 participants
Start Date 2025-03-25
Primary Completion 2029-04-28 (estimated)
Study Completion 2029-09-18 (estimated)
Updated on ClinicalTrials.gov 2026-09-11